Indinavir sulfate + Lamivudine + Zidovudine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Indinavir sulfate + Lamivudine + Zidovudine
Indinavir sulfate + Lamivudine + Zidovudine is a phase 3 stage product being developed by Merck for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00002410. Target conditions include HIV Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002410 | Phase 3 | Completed |
| NCT00002155 | Pre-clinical | Completed |
| NCT00002179 | Approved | Completed |
Competing Products
20 competing products in HIV Infections